Advice
Following a full submission.
Pregabalin (Lyrica®) is accepted for restricted use within NHS Scotland as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
It should be initiated only by physicians who have appropriate experience in the treatment of epilepsy and should be used principally in patients who have not benefited from treatment with an older anti-convulsant drug such as carbamazepine or sodium valproate, or for whom these drugs are unsuitable because of contra-indications, interaction or poor tolerance.
Download detailed advice47KB (PDF)
Medicine details
- Medicine name:
- Pregabalin (Lyrica®)
- SMC ID:
- 145/04
- Indication:
- Epilepsy
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 January 2005